Pharmaceutical Companies Turn to Space for Drug Development in Microgravity
Multiple pharmaceutical companies are conducting experiments in low Earth orbit to manufacture medicines in microgravity, which allows for more uniform crystal growth and better drug formulation. The absence of gravity eliminates sedimentation and convection that disrupt drug development on Earth, enabling higher-quality crystals that are easier to administer to patients. This emerging space pharma sector could represent a significant disruption to drug development as companies like Merck, Eli Lilly, and Bristol Myers Squibb pursue orbital manufacturing capabilities.
Pharmaceutical companies are increasingly moving drug development to lower Earth orbit, leveraging microgravity to improve medicine formulation. Companies like Redwire's SpaceMD subsidiary have developed specialized technologies such as the PIL-BOX, automated micro-laboratories that crystallize proteins in orbit. The absence of gravity eliminates gravitational disruptions like sedimentation and convection that occur on Earth, allowing scientists to grow more uniform, defect-free crystals. More uniform crystals result in lower viscosity, enabling complex therapies to be reformatted into thin, painless injections rather than requiring large needles or lengthy hospital infusions. Merck pioneered this approach in 2014 with experiments on the International Space Station involving its cancer drug Keytruda, demonstrating that space-grown antibodies produced highly uniform, stable mixtures. As aerospace infrastructure expands and companies like SpaceX pursue major IPOs, Morgan Stanley predicts the broader space economy could exceed $1 trillion by 2040, with pharmaceuticals positioned for immediate commercial disruption.
What's missing
The second source's headline suggests plant-based medicine manufacturing in space, but only the first source is provided in full; the actual content and details of the second source are not included, making it impossible to assess what additional context it may provide or how its framing differs.
What different sources said
- CNBCCenter
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
- ZME ScienceCenter
Astronauts Could Grow Their Own Medicines in Space Using Plants
Related
Chicago Woman's Five-Year Symptom Journey Leads to Rare Brain Tumor Diagnosis
Melony Aponte, 26, was diagnosed with a 4.5-centimeter acoustic neuroma after five years of symptoms she attributed to stress, COVID-19, and aging. The rare, noncancerous tumor—affecting roughly one in 100,000 people—had grown large enough to compress her hearing and balance nerve before it was identified via MRI in March 2025. Her case highlights how acoustic neuroma symptoms can mimic common conditions, potentially delaying diagnosis for years.
Study Finds Aging Shifts Walking Strategy Toward Stability at the Cost of Efficiency
A new study from Flinders University and the University of Canberra found that as people age, their bodies adopt a 'safety-first' walking pattern that prioritizes balance over efficient movement. Researchers analyzed gait data from 107 healthy adults aged 26 to 86, identifying increased ankle muscle co-contraction and reduced push-off power as key age-related changes. The findings suggest that fall prevention programs should target balance and coordination, not just muscle strength.
Tick Populations Surge in Urban Areas Across Northeast
Experts across the northeastern United States and Canada are warning of an unusually early and widespread tick season, with disease-carrying ticks increasingly found in urban parks and green spaces. Lyme disease cases in Canada reached a record 7,105 in 2025, up from 5,809 the previous year, while U.S. cities including Philadelphia, Pittsburgh, Washington D.C., and New York are reporting rising tick activity. The expansion poses a public health challenge because urban residents are less likely to take tick-bite precautions than those in rural areas.